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ABSTRACT: The preparation of oligonucleotides containing 8-bromo-2'-
deoxyguanosine is described. Substitution of G by 8-bromoguanine on an alternating 
CG decamer stabilizes the Z-form in such a way that the B-form was not observed. 
Melting temperatures showed that duplexes in which 8-bromo-2'-deoxyguanosine 
paired with natural bases were much less stable.  
 
 
Introduction 
     Chemically modified oligonucleotides are widely used in the study of nucleic acid 
structure and protein-nucleic acid interactions.1,2 Specifically, the introduction of 
brominated and iodinated nucleosides in defined positions is applied in the following 
areas: (a) photo-cross-linking with nucleic acid-binding proteins, in which the halogen 
is excised selectively to generate the nucleobase radicals,3 (b) in X-ray diffraction 
experiments, in which the higher electron density of the bromine and iodine is used to 
solve the phase problem,4 (c) mutagenesis studies, in which changes in pKa and/ or 
tautomerism induced by the halogen alter base pairing properties and polymerase 
fidelity.5 
     In the recent years interest has focused on purine nucleosides carrying bulky 
substituents at the 8-position to favor the syn conformation at the N-glycoside bond.6-8 
These oligonucleotides may be used as model compounds to study DNA fidelity and 
DNA repair. One of the most significant oxidative damage products in DNA is 8-oxo-
7,8-dihydro-2'-deoxyguanosine (8-oxoG).9 This lesion is repaired by several enzymes, 
and it has been suggested that the higher population of the syn conformation on 8-oxoG 
is the structural feature recognized by the repair enzymes to distinguish 8-oxoG and 
dG.10 Bulky substituents on purine nucleosides at the 8-position shift the equilibrium to 
the syn conformation.11 On the basis of these data, 8-bromo-2'-deoxyguanosine (B) was 
successfully used to probe syn-anti conformational preferences on G-quartet structures.6 
Moreover, bromination of poly (d(GC)) stabilizes the Z-DNA form.12 A modification of 
38% 8-bromoguanine and 18% 5-bromocytosine is enough to render a stable Z-DNA 
helix in physiological conditions.  
     Oligodeoxynucleotides containing 8-bromoguanine were prepared using the 
isobutyryl group for the protection of the amino group at position 2.6 In this 
communication we report the synthesis of an 8-bromoguanine phosphoramidite 
derivative protected with the dimethylformamidine (dmf)13,14 group and its use in the 
preparation of oligodeoxynucleotides carrying 8-bromoguanine. Moreover, base-pairing 
properties of oligodeoxynucleotides containing 8-bromoguanine and their ability to 
form Z-DNA are described. 
 
Results and Discussion 
 
Preparation of the protected phosphoramidite. The synthesis of the 8-bromoguanine 
phosphoramidite building block is illustrated in SCHEME 1. 8-Bromo-2'-
deoxyguanosine (1) was prepared from dG as described elsewhere.15 Reaction of 8-
bromo-2'-deoxyguanosine with N,N-dimethylformamide dimethyl acetal in 
dimethylformamide
16
 gave compound 2 which was used without purification in the 
following step. Compound 2 was treated with dimethoxytrityl (DMT) chloride in 
pyridine for 5 hours at room temperature yielding compound 3 in good yield (73% from 
1). Reaction of compound 3 with 2-cyanoethyl-N,N-diisopropyl chlorophosphine and 
N,N-diisopropylethylamine gave the desired phosphoramidite 4 in 90% yield. 
Moreover, the DMT-nucleoside 3 was converted to the 3'-O-hemisuccinate derivative 5, 
which was attached to amino-controlled pore glass (CPG, 500 Å) supports following 
previously described protocols (data not shown).17,18 
     One of the main differences between this and the previous preparation of isobutyryl-
protected 8-bromoguanine derivative,6 is that, bromination is performed before the 
introduction of the DMT and the amino protecting group. In this way some possible 
side reactions such as bromination of the DMT group and premature cleavage of the 
acid labile DMT group are avoided, resulting in a much higher yield. Also, the use of 
the more labile dmf group for the protection of the amino group results in a more 
versatile building block. 
 
Preparation of oligonucleotides. Oligonucleotides A (5' TB 3'), B (5' CACAB 3'), C 
(5' GCAATGGABCCTCTA 3') , D (5' CBCBCGCGCG 3'), E (5' 5B5BCGCGCG 3') 
and F (5' 5G5GCGCGCG 3') where B= 8-bromoguanine and 5= 5-bromocytosine were 
prepared on a DNA synthesizer using both standard (benzoyl-dA and dC and 
isobutyryl-dG) and t-butylphenoxyacetyl (TBPA)-protected19 2-cyanoethyl 
phosphoramidites together with phosphoramidite 4 and the commercially available 
phosphoramidite of 5-bromo-2'-deoxycytidine (protected with the benzoyl group) and 
the appropriate succinyl-CPG supports. During the syntheses, 0.02 M iodine solution 
(tetrahydrofurane: water: pyridine 7:1:2) was used to prevent the formation of N-cyano 
nucleosides.20 t-Butylphenoxyacetyl anhydride was used instead of acetic anhydride in 
the syntheses with TBPA-protected phosphoramidites to prevent acetylation of TBPA-
protected bases.19 After the assembly of the sequences, oligonucleotide-supports were 
treated with concentrated (30%) aqueous ammonia solution. The time needed for the 
removal of the dmf group on the dimer A was found to be less than 1 hour at room 
temperature, because a single peak was observed on reverse phase HPLC that had the 
expected molecular weight and the expected nucleoside composition after enzymatic 
digestion. Sequences carrying 5-bromocytosine (E and F) were prepared using t-
butylphenoxyacetyl (TBPA)-protected phosphoramidites and deprotected with 
concentrated ammonia at room temperature to avoid the formation of 5-
aminocytosine.21 Sequences B, C and D prepared with standard phosphoramidites were 
treated with concentrated ammonia overnight at 50ºC. Special attention was paid to 
detect the decomposition of 8-bromoguanine to 8-aminoguanine or 8-oxoguanine as it 
has been described for 5-bromo-pyrimidines21 and 8-bromo-dA22 when using hot 
ammonia solutions for the removal of protecting groups. In all cases, a major peak was 
observed that had the correct nucleoside composition (see FIG. 1) and the expected 
molecular weight. The higher stability of 8-bromoguanine to nucleophiles was also 
evident from the treatment of dimer A with lithium azide. This treatment was performed 
in order to obtain a dimer containing the photoreactive 8-azido-dG (data not shown). 
When support carrying sequence A was treated with 0.16 M lithium azide in DMF 
overnight at 50ºC, followed by ammonia deprotection (1 h, R.T.) the dimer containing 
unaltered 8-bromo-G was isolated. The same experiment with a similar dimer but 
containing 8-bromo-A instead of 8-bromo-G gave total conversion of 8-bromo-A dimer 
to the dimer containing 8-azido-A.23 Therefore, 8-bromoguanine oligonucleotides can 
be prepared without detectable degradation using the standard ammonia deprotection 
conditions (60 ºC, overnight). 
 
Melting experiments. Duplexes having 8-bromoguanine base pairs with the four 
natural bases were analyzed. Melting temperatures (Tm) are shown in TABLE 1. 
Guanine and 8-oxoguanine base pairs were included as reference. The oligonucleotide 
containing 8-oxoguanine were prepared as previously described.16 As expected in all 
cases the most stable base pair is formed between the guanine derivative and cytosine. 
The relative stability of the different guanine derivatives is G•C > 8-oxo-G•C > B•C. A 
similar trend is observed with the G•A mispairs. Duplex containing B•G basepair did 
not exhibit the cooperative helix-to-coil transition and for this reason Tm was not 
calculated. In contrast, G•T and 8-oxo-dG•T mispairs were less stable than B•T mispair. 
In general, melting temperatures of duplexes containing B were lower than 8-oxo-G and 
guanine duplexes. The degree of destabilization is similar to the destabilization found in 
duplexes containing 8-methoxy-dA.7 This destabilization has been assigned to a major 
content of the syn conformer that prevents the normal Watson-Crick hydrogen-
bonding.7 
 B to Z transition studies. Previously it was shown that bromination of poly (d(GC)) 
stabilizes the Z form12 but no data have appeared on the role of each individual reaction 
product: 5-bromocytosine and 8-bromoguanine. We addressed this question by 
preparing decamers containing alternating CG sequences in which two of the five 
residues were replaced by the corresponding bromo derivative. The contribution of each 
bromo derivative to the stabilization was estimated from the mid-point NaCl 
concentration for the B-Z transition of different self-complementary decamers measured 
by circular dichroism. As seen in TABLE 2, the presence of 5-bromocytosine induced 
only moderate stabilization of the Z-form (mid-point 1.2 M NaCl compared to a mid-
point of 2.2 M NaCl for d(CGCGCGCGCG)2 . On the other hand, 8-bromoguanine 
induces a large stabilization of the Z-form in such a way that even without NaCl added 
the CD spectra of 8-bromoguanine decamers correspond to the Z-form (see FIG. 2). The 
strong stabilization of the Z-form caused by 8-bromoguanine is in agreement with the 
strong stabilization observed for 8-methylguanine24 and 7-deaza-8-methylguanine.25,26 
Incorporation of 8-bromoguanine, 8-methylguanine or 7-deaza-8-methylguanine into 
oligonucleotides may be useful for the preparation of DNA substrates to study Z-DNA 
binding proteins,27,28 although we believe 8-bromoguanine oligonucleotides are easier to 
prepare. 
 
Conclusion 
     In conclusion, a new 8-bromo-dG phosphoramidite derivative is described. The new 
derivative is easily prepared and can be removed in mild conditions. Contrary to other 
brominated nucleosides21,22, 8-bromo-dG was found to be very stable to ammonia 
deprotection. Therefore, the use of more labile groups for the natural bases is not 
required. Substitution of G by 8-bromo-G destabilizes the duplex structure as expected 
from the higher content of the syn conformer, but it also strongly stabilizes the Z-form. 
Thus, 8-bromo-dG may be a useful probe for locating subtle differences in DNA 
polymerases29 and DNA repair glycosylases due to differences in conformational 
properties, and for producing substrates for the study of Z-DNA binding proteins.  
 
Experimental Section 
 
General Methods. All reactions were carried out in oven-dried glassware, under a 
nitrogen or argon atmosphere, unless specified otherwise. Before use, starting materials 
were dried by evaporation with the dry solvent which was later used for the reaction. 
Reagents for oligonucleotide synthesis were from Glen Research and PE Applied 
Biosystems. Dry solvents were from SDS and Romil. HPLC grade solvents were from 
Romil and E.Merck. Snake venom phosphodiesterase (from Crotalus durissus) and 
alkaline phosphatase were from Boehringer Mannheim. The rest of the reagents were 
from Aldrich and Fluka and were used without further purification. Analytical TLC was 
run on aluminum sheets coated with silica gel 60 F254 from Merck. Silica gel column 
chromatography was performed with Chromatogel 60 A C.C. (40-60 microns, 230-400 
mesh, SDS).  
 
Instrumental. 1H-NMR (250 MHz) 13C-NMR (63 MHz) and 31P-NMR (101 MHz) 
spectra were recorded on a Brüker AM-250. HPLC chromatography was performed on 
an HPLC System Gold (Beckman) and a Waters instrument. Mass spectra were 
obtained on a API III SCIEX-Perkin Elmer equipped with a triple quadrupole detector. 
 
5'-O-(Dimethoxytrityl)-N2-(N,N-dimethylaminomethyliden)-8-bromo-2'-
deoxyguanosine (3). 8-Bromo-2'-deoxyguanosine15 (1.5 g, 4.3 mmol) was reacted with 
N,N-dimethylformamide dimethyl acetal (1.72 ml, 15.9 mmol) in 20 cm3 of N,N-
dimethylformamide for 4 hours at room temperature giving quantitatively compound 2, 
which was used without purification in the following step.  
The residue of the previous reaction (compound 2) was dissolved in 20 ml of pyridine 
and treated with dimethoxytrityl chloride (6.5 mmol) for 5 hours at room temperature.  
Methanol ( 1 ml) was added to stop the reaction and the mixture was concentrated to 
dryness. The residue was dissolved in dichloromethane and washed with 1M aq. 
NaHCO3. The organic phase was dried and concentrated to dryness. The residue was 
purified on silica gel eluted with 0-10% methanol gradient in dichloromethane to afford 
compound 3 (2.2 g, 73% from 1) (Found: C, 57.7; H, 5.3; N, 12.1. C34H35N6O6 requires 
C, 58.0; H, 5.0; N, 11.9), Rf 0.10 (5% methanol in chloroform); δH(CD3OD) 2.29-2.42 
(2H, m), 2.98 (3H, s), 3.03 (3H, 1s), 3.16-3.49 (2H, m), 3.69 (6H, s), 4.05 (1H, m), 4.81 
(1H, m), 6.34 (1H, dd, J= 7.8 Hz, J= 4.4 Hz), 6.64 (4H, d, J= 5.8 Hz), 6.70 (4H, d, J= 
5.8 Hz), 7.05-7.42 (5H, m), 8.34 (1H, s), 8.50 (1H, d, J= 4.2 Hz); δC (CD3OD) 38.3, 
35.4, 41.6, 55.6, 65.0, 72.4, 87.0, 87.1, 87.4, 113.9, 121.6, 127.6, 129.1, 129.8, 130.9, 
131.1, 138.0, 138.1, 144.6, 152.5, 158.1, 159.0, 159.3, 150.9.  
 
3'-O-[(2-Cyanoethoxy)-(N,N-diisopropylamino)phosphinyl]-5'-O-(dimethoxytrityl)-
N
2
-[(N,N-dimethylamino)methyliden]-8-bromo-2'-deoxyguanosine(4). Compound 3 
(0.50 g, 0.74 mmol) was dissolved in dry acetonitrile and reacted with 0.20 ml (0.88 
mmol) of (2-cyanoethoxy)-(N,N-diisopropylamino)chlorophosphine and 0.40 ml (2.22 
mmol) of ethyldiisopropylamine. After 1 hour of magnetic stirring, the reaction was 
stopped by adding 1 ml of MeOH. The solvent was evaporated and the residue was 
dissolved in DCM (20 ml) and washed with 10% aq. NaHCO3 followed by saturated aq. 
NaCl. The organic phase was dried and concentrated to dryness. The residue was 
purified on silica gel eluted with dichloromethane/ ethyl acetate/ triethylamine 
(45:45:10) to give compound 4 (0.55 g, 90%) (Found: C, 56.7; H, 5.7; N, 12.7. 
C43H52N8O7BrP requires C, 57.1; H, 5.8; N, 12.4); Rf 0.8 (dichloromethane/ ethyl 
acetate/ triethylamine 45:45:10); δP (CH3CN, external reference H3PO4) 149.2 and 
149.3 (two diastereoisomers). 
 
Oligonucleotide synthesis. The following sequences have been synthesized:  A (5' TB 
3'), B (5' CACAB 3'), C (5' GCAATGGABCCTCTA 3'), D (5' CBCBCGCGCG 3'), E 
(5' 5B5BCGCGCG 3'), and F (5' 5G5GCGCGCG 3') being B= 8-bromo-G and 5= 5-
bromocytosine. Oligonucleotides were prepared on an automatic DNA synthesizer 
using commercially available 2-cyanoethyl phosphoramidites and the modified 
phosphoramidite. Oligonucleotide sequences B and C were prepared using using both 
standard (benzoyl-dA and dC and isobutyryl-dG) and t-butylphenoxyacetyl (TBPA)-
protected19 phosphoramidites. Oligonucleotide sequences E and F were prepared using 
using t-butylphenoxyacetyl (TBPA)-protected phosphoramidites as decribed.
23
 During 
the syntheses, 0.02 M iodine solution (tetrahydrofurane: water: pyridine 7:1:2) was used 
to prevent the formation of N-cyano nucleosides.
20
 t-Butylphenoxyacetyl anhydride was 
used instead of acetic anhydride on the syntheses with TBPA-protected 
phosphoramidites to prevent acetylation of TBPA-protected bases.
19 
     Oligonucleotide-supports were treated with 32% aqueous ammonia at 50 ºC for 16 h 
(when benzoyl and isobutyryl groups are used) and at room temperature for 16 hr (when 
TBPA groups are used). Ammonia solutions were concentrated to dryness and the 
products were purified either by cartridge purification (COP), by reversed phase HPLC 
or by PAGE electrophoresis. All purified products presented a major peak that was 
collected and analyzed by snake venom phosphodiesterase and alkaline phosphatase 
digestion followed by HPLC analysis of the nucleosides (HPLC conditions B, see FIG. 
2). HPLC solutions are as follows. Solvent A: 100 mM triethylammonium acetate (pH 
7.8) and solvent B: 50% ACN in 100 mM triethylammonium acetate pH 7.8. For 
analytical runs the following conditions were used. Column: Nucleosil 120C18, 250 x 4 
mm, flow rate: 1 ml min
-1
. Conditions A) a 40 min linear gradient from 0 to 100%B. 
Conditions B) a 20 min linear gradient from 0 to 40% B. For semipreparative runs the 
following conditions were used: Columns: Nucleosil 120C18, 250 x 10 mm. Flow rate: 3 
ml min
-1
. A 20 min linear gradient from 20-80% B (DMT-on), or a 30 min linear 
gradient from 0-60% B (DMT-off).  
     Mass spectra (electrospray) of dimer A: 648.9 and 650.9 (expected for 
C20H26N7O11PBr 649.3, 651.3), pentamer B: 1550.7 (expected for C48H60N21O26P5Br 
1549.7, 1551.7), pentadecamer C: 4654.3 (expected for C146H183N58O87P14Br 4654.2, 
4656.3), decamer D: 3186.3  (expected for C95H119N40O58P9Br2: 3187.6), decamer E: 
3344.6 (expected for C95H117N40O58P9Br4: 3345.6). 
 
Melting and circular dichroism experiments. Melting experiments of pentadecamers 
duplexes were performed as previously described.
17
 Duplex concentration was 4 μM. 
     Circular dichroism (CD) spectra were recorded on a Jasco J-710 spectropolarimeter 
with a Peltier temperature controller. CD measurements were taken at 20 ºC with a 5 
mm pathlength cell.  Duplex concentration was 4 μM. UV melting curves were 
performed with the samples from CD measurements. Melting temperatures of 
dodecamers were between 60 and 85 ºC depending on the oligonucleotide and the salt 
concentration. 
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TABLE 1. Melting Temperatures (Tm, ºC) of 8-bromoguanine (B) and 8-oxo-G 
duplexes (0.1 M sodium phosphate pH 7.0). 
 
5' GCA ATG GAX GCC TCT A 3' 
3' CGT TAC CTY CGG AGA T 5' 
 
 X = G X = B X = 8-oxo-G 
Y = C 62 56 60 
Y = A 55 49 55 
Y = G 55 n.c.# 54 
Y = T 54 56 50 
 
#curve with low hyperchromicity and not cooperative 
 
TABLE 2. Midpoint NaCl concentration in B->Z transitions for 8-bromoguanine (B) 
and 5-bromocytosine (5) oligodeoxynucleotides (50 mM tris HCl pH 7.5) 
 
Oligonucleotide NaCl (M)a 
d(CGCGCGCGCG)2 2.2 
d(5G5GCGCGCG)2 1.2 
d(CBCBCGCGCG)2 no transition, Z-form even at 0 M NaCl 
d(5B5BCGCGCG)2 no transition, Z-form even at 0 M NaCl 
 
a
In all cases the solutions were 50 mM Tris HCl buffer, pH 7.5 
 
 
 Figure Legends: 
 
SCHEME 1 : Preparation of the phosphoramidite derivative of N-protected-8-bromo-2'-
deoxyguanine. 
 
FIGURE 1 : Reversed phase chromatography analysis of the mixture obtained after 
phosphodiesterase and alkaline phosphatase degradation of purified pentadecamer C (5' 
GCA ATG GAB CCT CTA 3'). 
 
FIGURE 2 : CD spectra of decamers containing 5-bromocytosine and 8-bromoguanine 
in 50 mM Tris HCl buffer, pH 7.5, (without NaCl added) at 20 ºC.  
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